Login to Your Account



FDA Concerns Over Tarceva Send OSI's Stock Slumping

By Aaron Lorenzo


Tuesday, September 13, 2005
Shares in OSI Pharmaceuticals Inc. fell to a 52-week low, $30.74, in advance of an FDA panel hearing on Tarceva (erlotinib) as the agency released a briefing document questioning the product's benefit for pancreatic cancer patients in light of its risks. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription